The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Medtronic and Merit Medical Partner to Distribute ViaVerte Chronic Pain System

FDA and Novo Nordisk logos above a laboratory scene with computer monitors, chemical structures, medicine bottles, and pills.

Key Facts

1Medtronic signed a distribution agreement with Merit Medical Systems for the ViaVerte system.

2The ViaVerte system is an FDA-cleared, implant-free basivertebral nerve ablation (BVNA) system.

Medtronic (MDT) has entered into a strategic distribution agreement with Merit Medical Systems (MMSI) for the ViaVerte system. The ViaVerte system is an FDA-cleared, implant-free technology designed for basivertebral nerve ablation (BVNA) to treat chronic lower back pain. This partnership aims to address the rising demand for minimally invasive surgical interventions in the United States healthcare market. By integrating the ViaVerte platform, Medtronic expands its pain management portfolio with a steerable solution that avoids the need for permanent implants. For Merit Medical, the deal provides a powerful distribution channel to reach a broader patient base suffering from vertebrogenic pain. Analysts view this move as a positive step for both companies to capture a larger share of the specialized medical device market.